PRINCETON, N.J. , Sept.
17, 2024 /PRNewswire/ - Medunik USA , member of Duchesnay Pharmaceutical Group (DPG), one of the few anchor companies selected by the Government of Canada for its Global Hypergrowth Project, continues to increase Pheburane® coverage with three more states adding Pheburane® to their Medicaid Preferred Drug lists, namely Florida , Louisiana , and Maine , with Florida being one of the top states in terms of Medicaid spending on Urea Cycle Disorder (UCD) treatments. Thus, Pheburane® is now on the Preferred Drug list in 14 states and on the Contract Drugs list in California . This major achievement allows a greater number of patients with UCD to access this important treatment option through Medicaid programs.
Pheburane® is the safe, effective and palatable adjunctive therapy to the standard of care, which includes dietary management, for the treatment of certain UCDs. Pheburane® is an innovative formulation of sodium phenylbutyrate consisting of very small coated oral pellets and is indicated for both adult and pediatric patients. Pheburane® is not indicated for the treatment of acute hyperammonemia.
The most common side effects associated with sodium phenylbutyrate are menstrual dysfunction, decreased appetite, body odor and bad taste or taste aversion. 1 In addition to increasing the accessibility of Pheburane®, Medunik USA has expanded its UNIK Support program with the launch of a new Clinical Coordinator Outreach Program for patients and caregiv.